Long-term color stability of light-polymerized resin luting agents in different beverages

PurposeThe purpose of this study was to evaluate the long-term color stability of light-polymerized resin luting agents stored in different beverages.MethodsEleven shades of two light-polymerized resin luting agents, Choice2 (A1, A2, B1, TRANSLUCENT, MILKY OPAQUE, and MILKY BRIGHT) and BeautiCem Veneer (H-Value, M-Value, L-Value, Ivory-D, Ivory-L) were selected in this study. Disk-shaped specimens were fabricated with 1.3 mm thickness and 15.0 mm diameter. A total of 198 specimens, 18 for each shade, were prepared and randomly divided into six storage conditions (purified water, coffee, cola, tea, red wine, and air). All shades of specimens were three times measured at three random locations (n = 9) at 24 h storage in air after specimen preparation and then measured after immersion at 1, 3, 6, 9, and 12 mos. using a colorimeter. Then, the color difference (ΔE) between the specimens at 24 h after preparation and after storage in each liquid for 12 mos. was calculated. Statistical analysis was performed using Steele–Dwass multiple comparison test of the ΔE values or one-way ANOVA and Tukey's honest significant difference test.ResultsFor all immersion conditions, ΔE was significantly higher than air (control). The ΔE of the shades in the various storage conditions showed no significant difference between Purified Water-Cola and Coffee-Tea. Comparisons of the color components L*, a*, and b* for each shade showed different behaviors among the shades.ConclusionsThe results suggest that the color stability of light-polymerized resin luting agents may differ between different shades and beverages.</p

Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia

AbstractWe retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph+) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph+ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival